The Australian Journal of Hospital Pharmacy最新文献_第6页

Surgical Antibiotic Prophylaxis in a Private Hospital Compliance with Guidelines 私立医院的外科抗生素预防遵循指南

The Australian Journal of Hospital Pharmacy Pub Date : 1999-02-01 DOI: 10.1002/JPPR19992915

Kerri A McConachy, Sylvia Cuell, Paschal J. Kent, M. McDonald

引用次数: 4

Bring on the all-rounders 让全能型选手上场

The Australian Journal of Hospital Pharmacy Pub Date : 1999-02-01 DOI: 10.1002/JPPR199929148

G. Peterson

引用次数: 2

To manager and company director 致经理和公司董事

The Australian Journal of Hospital Pharmacy Pub Date : 1999-02-01 DOI: 10.1002/JPPR199929146

K. Deans

引用次数: 1

Pharmacy Services to Meet the Needs of Future Health Care 满足未来卫生保健需求的药学服务

The Australian Journal of Hospital Pharmacy Pub Date : 1999-02-01 DOI: 10.1002/JPPR199929131

F. May

引用次数: 1

Brave New World or Future Shock 美丽新世界还是未来冲击

The Australian Journal of Hospital Pharmacy Pub Date : 1999-02-01 DOI: 10.1002/JPPR19992912

J. Low

引用次数: 1

Drug usage evaluation of antimicrobial therapy for community-acquired pneumonia 社区获得性肺炎抗菌药物治疗的用药评价

The Australian Journal of Hospital Pharmacy Pub Date : 1999-01-01 DOI: 10.1002/JPPR1999296317

J. M. Radford, L. Cardiff, P. Pillans, D. Fielding, D. Looke

{"title":"Drug usage evaluation of antimicrobial therapy for community-acquired pneumonia","authors":"J. M. Radford, L. Cardiff, P. Pillans, D. Fielding, D. Looke","doi":"10.1002/JPPR1999296317","DOIUrl":"https://doi.org/10.1002/JPPR1999296317","url":null,"abstract":"Aim: To review antimicrobial therapy of community-acquired pneumonia (CAP) at the Princess Alexandra Hospital and compare management with institutional guidelines. Method: Clinical pharmacists prospectively reviewed 100 patients with a diagnosis of CAP during a five-week period in August and September 1998. Clinical and laboratory data were collected from patient records and assessed for compliance with institutional guidelines for the appropriate management of CAP. For the purposes of these guidelines, pneumonia severity was defined according to the clinical condition of the patient and their inherent risk factors. Results: Ninety-nine patients (99%) were prescribed an antibiotic for the treatment of CAP. Ninety-six patients were prescribed parenteral antibiotics for a mean of 7 days (range 0-27 days, median 6 days). Seventy-six patients were prescribed oral therapy for a mean duration of 10 days (range 3-21 days, median 9 days). Only 11 of 41 patients (27%) with severe pneumonia received IV erythromycin. Thirteen of 28 patients (46%) diagnosed with mild-moderate pneumonia were inappropriately treated with broad-spectrum parenteral agents. Only 45% of patients were treated appropriately. Thirty-three positive sputum cultures were reported (from 54 specimens) and four patients returned more than one isolate. Fourteen per cent of the patients admitted with CAP died during their admission. Conclusions: Community-acquired pneumonia is a major cause of death due to infection. This study showed an under-utilisation of parenteral antibiotics for severe pneumonia and an overuse of broad-spectrum parenteral antibiotics for moderate pneumonia without co-morbidities. New pneumonia management guidelines have been developed and a further review was recently undertaken in an attempt to reduce inappropriate management of CAP within our institution.","PeriodicalId":22283,"journal":{"name":"The Australian Journal of Hospital Pharmacy","volume":"2013 1","pages":"317-320"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86322744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

An Australian PharmD: Doctor of Clinical Pharmacy, The University of Queensland 澳大利亚药学博士:昆士兰大学临床药学博士

The Australian Journal of Hospital Pharmacy Pub Date : 1999-01-01 DOI: 10.1002/JPPR1999295284

L. Pulver, S. Tett

引用次数: 2

Compatibility of Paclitaxel in 5% Glucose and 0.9% Sodium Chloride Injections with EVA Minibags 紫杉醇与5%葡萄糖、0.9%氯化钠注射液EVA微袋的相容性研究

The Australian Journal of Hospital Pharmacy Pub Date : 1998-06-01 DOI: 10.1002/JPPR1998283156

Quanyu Xu, L. Trissel, Melvyn R Davis

{"title":"Compatibility of Paclitaxel in 5% Glucose and 0.9% Sodium Chloride Injections with EVA Minibags","authors":"Quanyu Xu, L. Trissel, Melvyn R Davis","doi":"10.1002/JPPR1998283156","DOIUrl":"https://doi.org/10.1002/JPPR1998283156","url":null,"abstract":"Aim: To evaluate the compatibility of a paclitaxel formulation ( Anzatax, Faulding) at concentrations of 0.3 and 1.2 mg/mL in 5% glucose injection and 0.9% sodium chloride injection with Baxter ethylene vinyl acetate (EVA) solution containers. We evaluated the potential for leachable materials to be extracted from the EVA bag by the paclitaxel formulation and the potential for paclitaxel loss due to sorption to the plastic. Method: The paclitaxel admixtures at both concentrations were prepared and stored at 25 and 32 degrees Celcius, protected from light, for 72 hours. All admixtures were prepared in triplicate in the EVA minibags; samples were drawn from the containers initially upon preparation and after 24 and 72 hours of storage. The paclitaxel concentrations of the samples and the extractable content from the container were determined using separate high performance liquid chromatographic methods. Leached material was analysed by mass spectrometer. Results: Paclitaxel was chemically stable throughout the 72-hour study period exhibiting no loss due to decomposition or sorption in any of the admixtures. However, an unknown material was leached from the EVA containers, appearing in both the 24- and 72-hour samples. The unknown material chromatographed very similarly to an unknown that was extracted by contact of the plastic with pure acetonitrile. The unknown primarily consisted of three entities having masses of 888.69, 932.68, and 976. 73 daltons and may be leached polymeric material varying in the number of associated acetate groups. Conclusion: Paclitaxel is chemically stable at 0.3 and 1.2 mg/mL in 5% glucose injection and in 0.9% sodium chloride injection in EVA containers for up to 72 hours at 25 and 32 degrees celcius. However, some material of unknown identity was leached into the drug admixture from the container within 24 hours. (author abstract)","PeriodicalId":22283,"journal":{"name":"The Australian Journal of Hospital Pharmacy","volume":"135 1","pages":"156-159"},"PeriodicalIF":0.0,"publicationDate":"1998-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79546178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

PBS, APAC & Hospital Pharmacy PBS，亚太地区和医院药房

The Australian Journal of Hospital Pharmacy Pub Date : 1998-06-01 DOI: 10.1002/JPPR1998283153

J. Low

引用次数: 1

Comparison of high-dose and standard-dose pancreatic enzyme capsules in children with cystic fibrosis 高剂量与标准剂量胰酶胶囊治疗儿童囊性纤维化的比较

The Australian Journal of Hospital Pharmacy Pub Date : 1998-06-01 DOI: 10.1002/JPPR1998283160

P. Robinson, G. Natoli

{"title":"Comparison of high-dose and standard-dose pancreatic enzyme capsules in children with cystic fibrosis","authors":"P. Robinson, G. Natoli","doi":"10.1002/JPPR1998283160","DOIUrl":"https://doi.org/10.1002/JPPR1998283160","url":null,"abstract":"Objective: To compare the efficacy of a high-dose, pancreatic enzyme supplement Creon Forte to that of a standard pancreatic enzyme supplement Cotazym S Forte in a group of children with cystic fibrosis. Methodology: 18 children with cystic fibrosis were enrolled in a 4-week open-labelled, randomised, two-period, crossover study in which equal doses of lipase were provided by either Creon Forte or Cotazym S Forte. Efficacy was determined by a 4-day faecal fat study at the end of each 2-week period. Patients were also asked to record daily the degree of abdominal symptoms including abdominal pain, abdominal bloating, diarrhoea, constipation, nausea, vomiting and anorexia. Results: No significant differences were found between the two enzyme preparations as assessed by fat absorption studies when equivalent doses of lipase were used. The mean fat absorption for Creon Forte was 89% and 91% for Cotazym S Forte (p>0.05). This allowed a 2.5-fold reduction in the number of capsules taken per day with Creon Forte compared to Cotazym S Forte. Scoring of abdominal symptoms were not significantly different between the two medications. The 14 patients who completed the trial preferred Creon Forte. Conclusions: Creon Forte is as effective as Cotazym S Forte in improving fat absorption in children with cystic fibrosis when equivalent doses of lipase are used with a lower number of capsules. (author abstract)","PeriodicalId":22283,"journal":{"name":"The Australian Journal of Hospital Pharmacy","volume":"15 1","pages":"160-164"},"PeriodicalIF":0.0,"publicationDate":"1998-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89750064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4